We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron (REGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Read MoreHide Full Article
Regeneron (REGN - Free Report) reported $3.36 billion in revenue for the quarter ended September 2023, representing a year-over-year increase of 14.5%. EPS of $11.59 for the same period compares to $11.14 a year ago.
The reported revenue represents a surprise of +3.92% over the Zacks Consensus Estimate of $3.24 billion. With the consensus EPS estimate being $10.80, the EPS surprise was +7.31%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Regeneron performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- Eylea (Aflibercept)- US: $1.45 billion compared to the $1.55 billion average estimate based on five analysts. The reported number represents a change of -11.1% year over year.
Revenues- Praluent (alirocumab)- US: $40.40 million versus $37.70 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +36% change.
Revenues- Kevzara (sarilumab)- ROW: $43.30 million compared to the $39.41 million average estimate based on four analysts. The reported number represents a change of +23.7% year over year.
Revenues- Dupixent (dupilumab)- US: $2.37 billion versus $2.29 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +29.7% change.
Revenues- Net product sales: $1.79 billion versus $1.82 billion estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -0.9% change.
Revenues- Other Revenue: $138 million versus $112.68 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +63.9% change.
Revenues- Collaboration: $1.44 billion versus $1.33 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +36.9% change.
Revenues- Collaboration revenue- Bayer: $377 million compared to the $371.25 million average estimate based on five analysts. The reported number represents a change of +13.2% year over year.
Revenues- Collaboration revenue- Sanofi: $1.07 billion versus $995.97 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +49.8% change.
Revenues- Praluent (alirocumab)- Total: $165.50 million compared to the $137.57 million average estimate based on four analysts. The reported number represents a change of +45.6% year over year.
Revenues- Kevzara (sarilumab)- Total: $95.70 million versus $93.70 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +8.6% change.
Revenues- Dupixent (dupilumab)- Total: $3.10 billion versus $2.97 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +32.9% change.
Shares of Regeneron have returned -2.9% over the past month versus the Zacks S&P 500 composite's -1.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Regeneron (REGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Regeneron (REGN - Free Report) reported $3.36 billion in revenue for the quarter ended September 2023, representing a year-over-year increase of 14.5%. EPS of $11.59 for the same period compares to $11.14 a year ago.
The reported revenue represents a surprise of +3.92% over the Zacks Consensus Estimate of $3.24 billion. With the consensus EPS estimate being $10.80, the EPS surprise was +7.31%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Regeneron performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Eylea (Aflibercept)- US: $1.45 billion compared to the $1.55 billion average estimate based on five analysts. The reported number represents a change of -11.1% year over year.
- Revenues- Praluent (alirocumab)- US: $40.40 million versus $37.70 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +36% change.
- Revenues- Kevzara (sarilumab)- ROW: $43.30 million compared to the $39.41 million average estimate based on four analysts. The reported number represents a change of +23.7% year over year.
- Revenues- Dupixent (dupilumab)- US: $2.37 billion versus $2.29 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +29.7% change.
- Revenues- Net product sales: $1.79 billion versus $1.82 billion estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -0.9% change.
- Revenues- Other Revenue: $138 million versus $112.68 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +63.9% change.
- Revenues- Collaboration: $1.44 billion versus $1.33 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +36.9% change.
- Revenues- Collaboration revenue- Bayer: $377 million compared to the $371.25 million average estimate based on five analysts. The reported number represents a change of +13.2% year over year.
- Revenues- Collaboration revenue- Sanofi: $1.07 billion versus $995.97 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +49.8% change.
- Revenues- Praluent (alirocumab)- Total: $165.50 million compared to the $137.57 million average estimate based on four analysts. The reported number represents a change of +45.6% year over year.
- Revenues- Kevzara (sarilumab)- Total: $95.70 million versus $93.70 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +8.6% change.
- Revenues- Dupixent (dupilumab)- Total: $3.10 billion versus $2.97 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +32.9% change.
View all Key Company Metrics for Regeneron here>>>Shares of Regeneron have returned -2.9% over the past month versus the Zacks S&P 500 composite's -1.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.